Submissions for reimbursement of a new health technology commonly include indirect treatment comparisons (ITCs), which provide evidence of how the product’s efficacy relates to that of comparators. The reimbursement decision may also depend on a consideration of ITCs in adverse events (AEs) and discontinuation endpoints.
In this paper, we present (1) an overview of the key issues of specific interest when conducting these ITCs, and (2) methods to potentially overcome these issues to maximize the validity of safety and tolerability estimates being considered in a reimbursement decision.
Fill out the form on the right to download the paper.
Download the pdf
"*" indicates required fields